Author Index

Ada, G.L. *see* Jones, P.D., 244
Ahuja, S. *see* Gupta, R.K., 102
Ahuja, S., Gupta, R.K., Sharma, S.B., Maheshwari, S.C., Bhandari, S.K. and Saxena, S.N. Further observations on the stability of cholera vaccine at different temperatures, 164
Allison, A.C. *see* Byars, N.E., 223
Amadori, M., Barei, S., Melegari, M. and Panina, G.F. Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions, 219
Ambrosch, F. *see* Wiedermann, G., 179
André, F.E. *see* Vesikari, T., 105
Au-Jensen, A. and Heron, I. Synergistic teratogenic effect produced in mice by whole cell pertussis vaccine, 215
Azuma, I. *see* Iida, J., 270
Azuma, I. *see* Ishihara, C., 295
Azuma, I. *see* Nishimura, K., 136

Baba, K. *see* Okuno, Y., 128
Bannatyne, R.M. and Jackowski, J. Protective effectiveness of an endotoxin-depleted pertussis vaccine, 268
Barei, S. *see* Amadori, M., 219
Barnea, B. *see* Fogel, A., 82
Barr, P.J., Steimer, K.S., Sabin, E.A., Parkes, D., Georges-Nascimento, C., Stephans, J.C., Powers, M.A., Gyenes, A., Van Nest, G.A., Miller, E.T., Higgins, K.W. and Lucin, P.A. Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast *Saccharomyces cerevisiae*, 90
Barth, R. *see* Nicholson, K.G., 208
Beckenhauer, W.H. *see* Haffer, K.N., 133
Bernard, F. *see* Plommet, M., 27
Beuvery, E.C. *see* Teerlink, T., 307
Beuvery, E.C. *see* van de Wiel, P.A., 33
Beyer, W.E.P., Versluis, D.J., Kramer, P., Diderich, Ph.P.M.N., Weimar, W. and Masurel, N. Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components, 43
Bhandari, S.K. *see* Ahuja, S., 164
Bijok, U. *see* Nicholson, K.G., 208
Blancou, J. *see* Tidke, R., 229
Bosseray, N. *see* Plommet, M., 27
Botros, B.A.M. *see* Kilpatrick, M.E., 260
Boulay, G. *see* Trudel, M., 239
Bratoeva, M. *see* Nenkov, P., 192
Brennan, J.-P. *see* Stetler, H.C., 169
Brookes, K. *see* Skinner, G.R.B., 55
Bruyere, T., Wachsmann, D., Klein, J.-P., Schöller, M. and Frank, R.M. Local response in rat liposome-associated *Streptococcus mutans* polysaccharide–protein conjugate, 39
Bucci, T.J. *see* Kilpatrick, M.E., 370
Buchan, A. *see* Skinner, G.R.B., 55
Byars, N.E. and Allison, A.C. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, 223

Carrasco, J.L. and Lardinois, R. Formula for calculating vaccine profitability, 123
Carreno, V. *see* Mora, I., 279
Castrucci, G. *see* Skinner, G.R.B., 55
Cellesi, C. *see* Valensin, P.E., 289
Chan, L.S. *see* Wilkins, J., 49
Christodoulides, M., Sidey, F.M., Parton, R. and Stewart-Tull, D.E.S. Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure, 199
Chung, K.W. *see* Chung, W.K., 175
Chung, W.K., Sun, H.S., Chung, K.W., Kim, B.S., Min, B.K. and Prince, A.M. Safety and immunogenicity of a new heat-inactivated hepatitis B virus vaccine in adult recipients, 175
Collotti, C. *see* Wirz, M., 211
Conti, S. *see* Wirz, M., 211
Coulon, P. *see* Tidke, R., 229
Cowan, M. *see* Skinner, G.R.B., 55
Cryz, Jr, S.J. Prospects for the prevention and control of Gram-negative nosocomial infections, 261
Cusi, M.G. *see* Valensin, P.E., 289

Dahl, R.J., Woods, W.H. and Johnson, A.M. Recognition by the human immune system of candidate vaccine epitopes of *Toxoplasma gondii* measured by a competitive ELISA, 187
Davies, A. *see* Gregoriadis, G., 145
Davies, J. *see* Skinner, G.R.B., 55
Davis, D. *see* Gregoriadis, G., 145
De Bel, C. *see* Wiedermann, G., 179
Delem, A. *see* Vesikari, T., 105
Denchev, V. *see* Nenkov, P., 192
Denning, C.R. *see* King, Jr, J.C., 234
Derks, H.J.G.M. *see* van de Wiel, P.A., 33
Devriese, L.A. *see* Okerman, L., 315
Diderich, Ph.P.M.N. *see* Beyer, W.E.P., 43
Durham, J. *see* Skinner, G.R.B., 55

Ehara, M., Ishibashi, M., Ichinose, Y., Iwanaga, M., Shimotori, S. and Naito, T. Purification and partial characterization of fimbriae of *Vibrio cholerae* O1, 283
Evenberg, D. *see* Teerlink, T., 307
Evenberg, D. *see* van de Wiel, P.A., 33

Farro, P.R. *see* Nicholson, K.G., 208
Farzadegen, H. *see* Ndikuyeze, A., 168
Flamand, A. *see* Tidke, R., 229
Fogel, A., Gerichter, Ch.B. and Barnea, B. Prevention of rubella infection among women of child-bearing age by screening and vaccination. Assessment during a nationwide rubella epidemic in Israel, 82
Fonseca, L.S. *see* Mortatti, R.C., 109
Frank, R.M. *see* Bruyere, T., 39
Frasch, C.E. Prospects for the prevention of meningococcal disease: special reference to group B, 3

Gaerlan, P.F. *see* King, Jr, J.C., 234
Gentili, G. *see* Wirz, M., 211
Georges-Nascimento, C. *see* Barr, P.J., 90
Gerichter, Ch.B. *see* Fogel, A., 82
Gesemann, M. *see* Wiedermann, G., 179
Goubau, P. *see* Wiedermann, G., 179
Gregoriadis, G., Davis, D. and Davies, A. Liposomes as immunological adjuvants: antigen incorporation studies, 145
Gross, P.A. *see* King, Jr, J.C., 234
Gupta, R.K. *see* Ahuja, S., 164
Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. Glutaraldehyde inactivated pertussis vaccine: a safe vaccine in the innocuity test, 102
Gyenes, A. *see* Barr, P.J., 90

Haffer, K.N., Sharpee, R.L. and Beckenhauer, W.H. Feline leukaemia vaccine protection against viral latency, 133
Hashizume, S. *see* Morita, M., 65
Hauser, P. *see* Wiedermann, G., 179
Heron, I. *see* Au-Jensen, A., 215
Heron, I. *see* Simonsen, O., 115
Hingley, P.J. *see* Pay, T.W.F., 60
Hinman, A.R. *see* Stetler, H.C., 169

Ichinose, Y. *see* Ehara, M., 283
Iida, J. *see* Ishihara, C., 295
Iida, J., Une, T., Ishihara, C., Nishimura, K., Tokura, S., Mizukoshi, N.

and Azuma, I. Stimulation of non-specific host resistance against Sendai virus and *Escherichia coli* infections by chitin derivatives in mice, 270
Ishibashi, M. *see* Ehara, M., 283
Ishihara, C. *see* Iida, J., 270
Ishihara, C., Mizukoshi, N., Iida, J., Kato, K., Yamamoto, K. and Azuma, I. Suppression of Sendai virus growth by treatment with N^{α}-Acetylmuramyl-L-alanyl-D-isoglutaminyl-N^{ε}-stearoyl-L-lysine in mice, 295
Isolauri, E. *see* Vesikari, T., 105
Iwanaga, M. *see* Ehara, M., 283

Jackowski, J. *see* Bannatyne, R.M., 268
Jacob John, T. *see* Selvakumar, R., 141
Johnson, A.M. *see* Dahl, R.J., 187

Kajima, K. *see* Morita, M., 65
Kato, K. *see* Ishihara, C., 295
Kilpatrick, M.E., Botros, B.A.M., Bucci, T.J. and Ross, S.A. Value of pre-exposure rabies human diploid cell vaccine for individuals living in areas hyperendemic for rabies, 260
Kim, B.S. *see* Chung, W.K., 175
King, Jr, J.C., Gross, P.A., Denning, C.R., Gaerlan, P.F., Wright, P.F. and Quinnan, Jr, G.V. Comparison of live and inactivated influenza vaccine in high risk children, 234
Kitchen, L.W. Effect of diethylcarbamazine on cats given feline leukaemia virus vaccine, 266
Kjeldsen, K. *see* Simonsen, O., 115
Klein, J.-P. *see* Bruyere, T., 39
Kobayashi, H. *see* Morita, M., 65
Kojima, A. *see* Morita, M., 65
Kramer, P. *see* Beyer, W.E.P., 43
Kremsner, P. *see* Wiedermann, G., 179
Kunz, C. *see* Wiedermann, G., 179

Lai, K.-H. *see* Lee, S.-D., 195
Lantier, F. *see* Plommet, M., 27
Lardinois, R. *see* Carrasco, J.L., 123
Lee, S.-D., Lo, K.-J., Tsai, Y.-T., Wang, J.-Y., Lai, K.-H., Wu, J.-C. and Wu, T.-C. Hepatitis B vaccination in healthy Chinese adults with low dose regimens, 195
Lehtinen, M. Affinity and sub-class distribution of IgG-class antibodies following vaccination with a live rubella virus vaccine, 88
Lifely, M.R., Moreno, C. and Lindon, J.C. An integrated molecular and immunological approach towards a meningococcal group B vaccine, 11
Lindon, J.C. *see* Lifely, M.R., 11
Livengood, J.R. *see* Stetler, H.C., 169
Lo, K.-J. *see* Lee, S.-D., 195
Lussier, G. *see* Trudel, M., 239

Maheshwari, S.C. *see* Ahuja, S., 164
Maia, L.C.S. *see* Mortatti, R.C., 109
Manning, P.A. Involvement of cell envelope components in the pathogenesis of *Vibrio cholerae*: targets for cholera vaccine development, 83
Marinova, S. *see* Nenkov, P., 192
Masurel, N. *see* Beyer, W.E.P., 43
May, A. *see* Nicholson, K.G., 302
Melegari, M. *see* Amadori, M., 219
Miller, E.T. *see* Barr, P.J., 90
Min, B.K. *see* Chung, W.K., 175
Mizukoshi, N. *see* Iida, J., 270
Mizukoshi, N. *see* Ishihara, C., 295
Mora, I., Porres, J.C. and Carreno, V. Receptors for polymerized human serum albumin in plasma derived hepatitis B vaccines, 279
Moreno, C. *see* Lifely, M.R., 11
Morita, M., Suzuki, K., Yasuda, A., Kojima, A., Sugimoto, M., Watanabe, K., Kobayashi, H., Kajima, K. and Hashizume, S. Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen preserving the attenuation of the parental virus strain, 65
Mortatti, R.C., Maia, L.C.S. and Fonseca, L.S. Absorption of *Mycobacterium bovis* BCG administered by the oral route, 109
Mullen, J.R. *see* Stetler, H.C., 169

Nadon, F. *see* Trundel, M., 239
Naito, T. *see* Ehara, M., 283
Ndikuyeze, A., Taylor, E., Farzadegen, H. and Polk, B.F. Measles immunization in children with human immunodeficiency virus infection, 168
Nenkov, P., Bratoeva, M., Marinova, S. and Denchev, V. Technological investigations with attenuated strains of *Shigella* for production of live vaccines. 1. Cultivation in a fermeneter of an attenuated strain. *S. flexneri* 2a with two markers, 192
Newman, J.F.E. *see* Martin, M.E.D., 430
Nicholson, K.G., Farro, P.R., Bijok, U. and Barth, R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man, 208
Nicholson, K.G., Wiselka, M.J. and May, A. Influenza vaccination of the elderly: perceptions and policies of general practitioners and outcome of the 1985–86 immunization programme in Trent, 302
Nishi, N. *see* Nishimura, K., 136
Nishimura, K. *see* Iida, J., 270
Nishimura, K., Nishimura, S.-I., Seo, H., Nishi, N., Tokura, S. and Azuma, I. Effect of multiporous microspheres derived from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages, 136
Nishimura, S.-I. *see* Nishimura, K., 136

Okamoto, Y. *see* Okuno, Y., 128
Okerman, L. and Devriese, L.A. Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit *Pasteurella multocida* vaccine, 315
Okuno, Y., Okamoto, Y., Yamada, A., Baba, K. and Yabuuchi, H. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus, 128
Orenstein, W.A. *see* Stetler, H.C., 169

Paar, D. *see* Wiedermann, G., 179
Pana, A. *see* Wirz, M., 211
Panina, G.F. *see* Amadori, M., 219
Pardon, P. *see* Plommet, M., 27
Parkes, D. *see* Barr, P.J., 90
Parton, R. *see* Christodoulides, M., 199
Pasquini, P. *see* Wirz, M., 211
Pay, T.W.F. and Hingley, P.J. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level protection induced in cattle by foot-and-mouth disease vaccines, 60
Peters, A.R. Vaccines for respiratory disease in cattle, 164
Plommet, M., Bosseray, N., Lantier, F., Bernard, F., Pardon, P. and Rodolakis, A. Simultaneous vaccination by three living attenuated strains of *Brucella, Salmonella* and *Chlamydia* in mice, 27
Polk, B.F. *see* Ndikuyeze, A., 168
Porres, J.C. *see* Mora, I., 279
Powers, M.A. *see* Barr, P.J., 90
Prehaud, C. *see* Tidke, R., 229
Prince, A.M. *see* Chung, W.K., 175

Quinnan, Jr, G.V. *see* King, Jr, J.C., 234

Rautanen, T. *see* Vesikari, T., 105
Rodolakis, A. *see* Plommet, M., 27
Rosmini, F. *see* Wirz, M., 211
Ross, S.A. *see* Kilpatrick, M.E., 260
Rossolini, A. *see* Valensin, P.E., 289
Rossolini, G.M. *see* Valensin, P.E., 289

Sabin, E.A. *see* Barr, P.J., 90
Saxena, S.N. *see* Ahuja, S., 164
Saxena, S.N. *see* Gupta, R.K., 102
Scheiermann, N. *see* Wiedermann, G., 179
Schöller, M. *see* Bruyere, T., 39
Seguin, C. *see* Trudel, M., 239
Selvakumar, R. and Jacob John, T. Intestinal immunity induced by inactivated poliovirus vaccine, 141
Seo, H. *see* Nishimura, K., 136
Sharma, S.B. *see* Ahuja, S., 164
Sharma, S.B. *see* Gupta, R.K., 102
Sharpee, R.L. *see* Haffer, K.N., 133
Shimotori, S. *see* Ehara, M., 283
Sidey, F.M. *see* Christodoulides, M., 199

Simonsen, O., Weiz Bentzon, M., Kjeldsen, K., Venborg, H.-A. and Heron, I. Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus, 115
Skinner, G.R.B., Buchan, A., Durham, J., Cowan, M., Davies, J., Brookes, K. and Castrucci, G. Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects, 55
Smith, D.T. Recent developments in the design and construction of facilities for the production of human injectables, 5
Steimer, K.S. *see* Barr, P.J., 90
Stephans, J.C. *see* Barr, P.J., 90
Stetler, H.C., Mullen, J.R., Brennan, J.-P., Livengood, J.R., Orenstein, W.A. and Hinman, A.R. Monitoring system for adverse events following immunization, 169
Stewart-Tull, D.E.S. *see* Christodoulides, M., 199
Sugimoto, M. *see* Morita, M., 65
Sun, H.S. *see* Chung, W.K., 175
Suzuki, K. *see* Morita, M., 65

Taylor, E. *see* Ndikuyeze, A., 168
Teerlink, T., Beuvery, E.C., Evenberg, D. and van Wezel, T.L. Synergistic effect of detergents and aluminium phosphate on the humoral immune response to bacterial and viral membrane proteins, 307
Terzi, I. *see* Wirz, M., 211
Tidke, R., Prehaud, C., Coulon, P., Blancou, J. and Flamand, A. Characterization of a double avirulent mutant of rabies and its potency as a vaccine, live or inactivated, 229
Tokura, S. *see* Iida, J., 270
Tokura, S. *see* Nishimura, K., 136
Trudel, M., Nadon, F., Seguin, C., Boulay, G. and Lussier, G. Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs, 239
Tsai, Y.-T. *see* Lee, S.-D., 195

Une, T. *see* Iida, J., 270

Valensin, P.E., Rossolini, G.M., Cusi, M.G., Zanchi, A., Cellesi, C. and Rossolini, A. Specific antibody patterns over a two-year period after rubella immunization with RA 27/3 live attenuated vaccine, 289
van de Wiel, P.A., Witvliet, M.H., Evenberg, D., Derks, H.J.G.M. and Beuvery, E.C. *O*-Polysaccharide–protein conjugates induce high levels of specific antibodies to *Pseudomonas aeruginosa* immunotype 3 lipopolysaccharide, 33
Van Nest, G.A. *see* Barr, P.J., 90
van Wezel, T.L. *see* Teerlink, T., 307
Venborg, H.-A. *see* Simonsen, O., 115
Versluis, D.J. *see* Beyer, W.E.P., 43
Vesikari, T., Rautanen, T., Isolauri, E., Delem, A. and André, F.E. Immunogenicity and safety of a low passage level bovine rotavirus candidate vaccine RIT 4256 in human adults and young infants, 105

Wachsmann, D. *see* Bruyere, T., 39
Wang, J.-Y. *see* Lee, S.-D., 195
Watanabe, K. *see* Morita, M., 65
Watson, D.L. Serological response of sheep to live and killed *Staphylococcus aureus* vaccines, 275
Wehrle, P.F. *see* Wilkins, J., 49
Weimar, W. *see* Beyer, W.E.P., 43
Weiz Bentzon, M. *see* Simonsen, O., 115
Wiedermann, G., Scheiermann, N., Goubau, P., Ambrosch, F., Gesemann, M., De Bel, C., Kremsner, P., Paar, D., Kunz, C., Hauser, P., Simoen, E., Safary, A., André, F.E. and Desmyter, J. Multicentre dose range study of a yeast-derived hepatitis B vaccine, 179
Wilkins, J., Chan, L.S. and Wehrle, P.F. Age and dose interval as factors in agglutinin formation to pertussis vaccine, 49
Wirz, M., Gentili, G., Rosmini, F., Collotti, C., Pana, A., Terzi, I., Conti, S. and Pasquini, P. Prevalence of hyperimmunization against tetanus in a national sample of 18–26 year old immune subjects in Italy, 211
Wiselka, M.J. *see* Nicholson, K.G., 302
Witvliet, M.H. *see* van de Wiel, P.A., 33
Woods, W.H. *see* Dahl, R.J., 187
Wright, P.F. *see* King, Jr, J.C., 234
Wu, J.-C. *see* Lee, S.-D., 195
Wu, T.-C. *see* Lee, S.-D., 195

Yabuuchi, H. *see* Okuno, Y., 128
Yamada, A. *see* Okuno, Y., 128
Yamamoto, K. *see* Ishihara, C., 295
Yasuda, A. *see* Morita, M., 65

Zanchi, A. *see* Valensin, P.E., 289
Zuckerman, A. Tomorrow's hepatitis B vaccines, 165

Subject Index

Adjuvant: Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, 223
Adjuvant: *see* Liposomes, 145
Adjuvant: *see Pasteurella multocida*, 315
Adjuvant: Synergistic effect of detergents and aluminium phosphate on the humoral immune response to bacterial and viral membrane proteins, 307
Adverse reactions: Monitoring system for adverse events following immunization, 169
Agglutinin: *see* Pertussis, 49
Albumin, polymerized human serum: Receptors for polymerized human serum albumin in plasma derived hepatitis B vaccines, 279
Antibodies: *see* Feline leukaemia virus, 266
Antibodies: *see Pseudomonas aeruginosa*, 33
Antibody affinity: *see* Rubella, 88
Antibody response: *see* Japanese encephalitis, 128
Antibody-secreting cells: *see* Influenza, 244
Antitoxin levels: *see* Tetanus, 115
Attenuated vaccine RA 27/3: *see* Rubella, 289
Attenuation: *see Shigella flexneri*, 192

BCG vaccine: *see Mycobacterium bovis*, 109
Bone marrow culture: *see* Feline leukaemia virus, 133
Bovine herpesvirus: Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs, 239
Bovine mammillitis virus: Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects, 55
Brucella: Simultaneous vaccination by three living attenuated strains of *Brucella*, *Salmonella* and *Chlamydia* in mice, 27

Carbodiimide: *see* Pertussis, 199
Cattle: *see* Foot-and-mouth disease, 60

Cattle: *see* Respiratory disease, 164
Cell envelope components: *see* Cholera, 83
Cell-mediated immunity: *see* Adjuvant, 223
Chick embryo cell culture: *see* Rabies, 208
Children: *see* Measles, 168
Children: *see* Pertussis, 49
Children: *see* Rubella, 289
Chitin, deacetylated: *see* Microspheres, multiporous, 136
Chitin derivatives: *see* Sendai virus, 270
Chlamydia: *see Brucella*, 27
Cholera: Involvement of cell envelope components in the pathogenesis of *Vibrio cholerae*: targets for cholera vaccine development, 83
Cholera: Further observations on the stability of cholera vaccine at different temperatures, 164
Cholera: *see Vibrio cholerae*, 283
Clean room: *see* Injectables, 5
Cold-adapted virus: *see* Influenza, 244
Conference Reports, 75, 157, 257
Cost–benefit analysis: *see* Profitability, 123
Cross-reactivity: *see* Bovine mammillitis virus, 55
Cystic fibrosis: *see* Influenza, 234

Detergent: *see* Adjuvant, 307
Diethylcarbamazine: *see* Feline leukaemia virus, 266
Dose response: *see* Foot-and-mouth disease, 60
DPT vaccine: *see* Pertussis, 102

ELISA, competitive: *see Toxoplasma gondii*, 187
Endonuclease inactivation: *see* Foot-and-mouth disease, 219
Endotoxin: *see* Pertussis, 215
Endotoxin-depleted vaccine: *see* Pertussis, 268
Envelope polypeptide: *see* Human immunodeficiency virus, 90
Epitope: *see Toxoplasma gondii*, 187
Escherichia coli: *see* Sendai virus, 270

Feline leukaemia virus: Effect of diethylcarbamazine on cats given feline leukaemia virus vaccine, 266
Feline leukaemia virus: Feline leukaemia vaccine protection against viral latency, 133
Fermenter culture: *see Shigella flexneri*, 192
Fimbriae: *see Vibrio cholerae*, 283
Foot-and-mouth disease: Correlation of 140S antigen dose with the serum neutralizing antibody response and the level protection induced in cattle by foot-and-mouth disease vaccines, 60
Foot-and-mouth disease: Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions, 219

Gram-negative bacteria: *see* Nosocomial infection, 261

Haemodialysis: *see* Influenza, 43
Heat-inactivated HBV vaccine: *see* Hepatitis B, 175
Hepatitis B: *see* Albumin, polymerized human serum, 279
Hepatitis B: Hepatitis B vaccination in healthy Chinese adults with low dose regimens, 195
Hepatitis B: Multicentre dose range study of a yeast-derived hepatitis B vaccine, 179
Hepatitis B: Safety and immunogenicity of a new heat-inactivated hepatitis B virus vaccine in adult recipients, 175
Hepatitis B: Tomorrow's hepatitis B vaccines, 165
Hepatitis B: *see* Vaccinia virus, 65
Herpes simplex virus: *see* Bovine mammillitis virus, 55
Human diploid cell culture: *see* Rabies, 208
Human diploid cell vaccine: *see* Rabies, 260
Human immunodeficiency virus: Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast *Saccharomyces cerevisiae*, 90
Human immunodeficiency virus: *see* Hepatitis B, 165
Human immunodeficiency virus: *see* Measles, 168
Humoral immunity: *see* Adjuvant, 223
Hyperimmunization: *see* Tetanus, 211

Immunity, continuous: *see* Tetanus, 115
Immunogenicity: *see* Influenza, 43
Immunogenicity: *see* Meningitis, 3, 11
Immunogenicity: *see* Rotavirus, 105
Immunoglobulin G: *see* Rubella, 88
Infectious bovine rhinotracheitis: *see* Bovine herpesvirus, 239
Influenza: Comparison of live and inactivated influenza vaccine in high risk children, 234
Influenza: Influenza-specific antibody-secreting cells and B cell memory in the murine lung after immunization with wild-type, cold-adapted variant and inactivated influenza viruses, 244
Influenza: Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components, 43
Injectables: Recent developments in the design and construction of facilities for the production of human injectables, 5
Innocuity test: *see* Pertussis, 102
Intestinal immunity: *see* Poliovirus, 141
Intranasal route: *see* Influenza, 234
ISCOMs: *see* Bovine herpesvirus, 239

Japanese encephalitis: Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus, 128

Latency: *see* Feline leukaemia virus, 133
Letters, 82, 168
Liposomes: Liposomes as immunological adjuvants: antigen incorporation studies, 145
Liposomes: *see Streptococcus mutans*, 39
Low dose: *see* Hepatitis B, 195

Macrophage activation: *see* Microspheres, multiporous, 136
Measles: Measles immunization in children with human immunodeficiency virus infection, 168
Meningitis: An integrated molecular and immunological approach toward a meningococcal group B vaccine, 11
Meningitis: Prospects for the prevention of meningococcal disease: special reference to group B, 3
Mentally retarded: *see* Hepatitis B, 420
Microspheres, multiporous: Effect of multiporous microspheres from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages, 136
Monitoring system: *see* Adverse reactions, 169
Muramyl dipeptide: Suppression of Sendai virus growth by treatment with N^{α}-acetylmuramyl-L-alanyl-D-isoglutaminyl-N^{ε}-stearoyl-L-lysine in mice, 295
Mutant: *see* Rabies, 229
Mycobacterium bovis: Absorption of *M. bovis* BCG administered by the oral route, 109

Neisseria gonorrhoeae: *see* Adjuvant, 307
Neutralization response: *see* Japanese encephalitis, 128

Nosocomial infection: Prospects for the prevention and control of Gram-negative nosocomial infections, 261

Oil: *see Pasteurella multocida*, 315
Oral vaccine, live: *see* Cholera, 83
Oral vaccine: *see Mycobacterium bovis*, 109

Pasteurella multocida: Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit *Pasteurella multocida* vaccine, 315
Patent Reports, 71, 152, 249, 319
Pertussis: Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure, 199
Pertussis: Age and dose interval as factors in agglutinin formation to pertussis vaccine, 49
Pertussis: Glutaraldehyde inactivated pertussis vaccine: a safe vaccine in the innocuity test, 102
Pertussis: Protective effectiveness of an endotoxin-depleted pertussis vaccine, 268
Pertussis: Synergistic teratogenic effect produced in mice by whole cell pertussis vaccine, 215
Poliovirus: Intestinal immunity induced by inactivated poliovirus vaccine, 141
Polysaccharide, group B: *see* Meningitis, 3, 11
Polysaccharide–protein conjugate: *see Pseudomonas aeruginosa*, 33
Polysaccharide–protein conjugate: *see Streptococcus mutans*, 39
Pre-exposure vaccination: *see* Rabies, 260
Profitability: Formula for calculating vaccine profitability, 123
Pseudomonas aeruginosa: *O*-Polysaccharide–protein conjugates induce high levels of specific antibodies to *P. aeruginosa* immunotype 3 lipopolysaccharide, 33

Rabies: Characterization of a double avirulent mutant of rabies virus and its potency as a vaccine, live or inactivated, 229
Rabies: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man, 208
Rabies: Value of pre-exposure rabies human diploid cell vaccine for individuals living in areas hyperendemic for rabies, 260
Reassortment: *see* Influenza, 440
Receptors: *see* Albumin, polymerized human serum, 279
Recombinant: *see* Vaccinia virus, 65
Reduced dose: *see* Hepatitis B, 195
Respiratory disease: Vaccines for respiratory disease in cattle, 164
Rotavirus: Immunogenicity and safety of a low passage level bovine rotavirus candidate vaccine RIT 4256 in human adults and young infants, 105
Rubella: Affinity and sub-class distribution of IgG-class antibodies following vaccination with a live rubella virus vaccine, 88
Rubella: Prevention of rubella infection among women of child-bearing age by screening and vaccination. Assessment during a nationwide rubella epidemic in Israel, 82
Rubella: Specific antibody patterns over a two-year period after rubella immunization with RA 27/3 live attenuated vaccine, 289

Saccharomyces cerevisiae: *see* Human immunodeficiency virus, 90
Safety: *see* Rotavirus, 105
Salmonella: *see Brucella*, 27
Screening: *see* Rubella, 82
Sendai virus: *see* Muramyl dipeptide, 295
Sendai virus: Stimulation of non-specific host resistance against Sendai virus and *Escherichia coli* infections by chitin derivatives in mice, 270
Seroepidemiology: *see* Tetanus, 211
Sheep: *see Staphylococcus aureus*, 275
Shigella flexneri: Technological investigations with attenuated strains of *Shigella* for production of live vaccines. 1. Cultivations in a fermenter of an attenuated strain *S. flexneri* 2a with two markers, 192
Stability: *see* Cholera, 164
Staphylococcus aureus: Serological response of sheep to live and killed *S. aureus* vaccines, 275
Sterile environment: *see* Injectables, 5
Streptococcus mutans: Local response in rat liposome-associated *Streptococcus mutans* polysaccharide-protein conjugate, 39

Temperature of storage: *see* Cholera, 164
Teratogenic effect: *see* Pertussis, 215
Tetanus: Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus, 115
Tetanus: Prevalence of hyperimmunization against tetanus in a national sample of 18–26 year old immune subjects in Italy, 211
Tetanus toxoid: *see* Liposomes, 145
Toxoid: *see* Pertussis, 199
Toxoplasma gondii: Recognition of the human immune system of candidate vaccine epitopes of *Toxoplasma gondii* measured by a competitive ELISA, 187

Vaccination campaign: *see* Profitability, 123
Vaccinia virus: Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen preserving the attenuation of the parental virus strain, 65
Vibrio cholerae: Purification and partial characterization of fimbriae of *V. cholerae* O1, 283
Virions: *see* Foot-and-mouth disease, 219

Yeast-derived HBV vaccine: *see* Hepatitis B, 179